These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 38649630)

  • 21. Promising vaccines for treating glioblastoma.
    Swartz AM; Shen SH; Salgado MA; Congdon KL; Sanchez-Perez L
    Expert Opin Biol Ther; 2018 Nov; 18(11):1159-1170. PubMed ID: 30281978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GBM immunotherapy: Exploring molecular and clinical frontiers.
    Ghosh MK; Kumar S; Begam S; Ghosh S; Basu M
    Life Sci; 2024 Nov; 356():123018. PubMed ID: 39214286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining immunotherapy with radiation for the treatment of glioblastoma.
    Chow KK; Hara W; Lim M; Li G
    J Neurooncol; 2015 Jul; 123(3):459-64. PubMed ID: 25877468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.
    Seyfrid M; Maich WT; Shaikh VM; Tatari N; Upreti D; Piyasena D; Subapanditha M; Savage N; McKenna D; Mikolajewicz N; Han H; Chokshi C; Kuhlmann L; Khoo A; Salim SK; Archibong-Bassey B; Gwynne W; Brown K; Murtaza N; Bakhshinyan D; Vora P; Venugopal C; Moffat J; Kislinger T; Singh S
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.
    Inocencio JF; Mitrasinovic S; Asad M; Parney IF; Zang X; Himes BT
    Front Immunol; 2024; 15():1424396. PubMed ID: 39346924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End.
    Datsi A; Sorg RV
    Front Immunol; 2021; 12():770390. PubMed ID: 34795675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances and future of immunotherapy for glioblastoma.
    Kamran N; Calinescu A; Candolfi M; Chandran M; Mineharu Y; Asad AS; Koschmann C; Nunez FJ; Lowenstein PR; Castro MG
    Expert Opin Biol Ther; 2016 Oct; 16(10):1245-64. PubMed ID: 27411023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microglia-Centered Combinatorial Strategies Against Glioblastoma.
    Martins TA; Schmassmann P; Shekarian T; Boulay JL; Ritz MF; Zanganeh S; Vom Berg J; Hutter G
    Front Immunol; 2020; 11():571951. PubMed ID: 33117364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine-based immunotherapy for glioblastoma.
    Thomas AA; Fisher JL; Ernstoff MS; Fadul CE
    CNS Oncol; 2013 Jul; 2(4):331-49. PubMed ID: 25054578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
    Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
    J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current vaccine trials in glioblastoma: a review.
    Xu LW; Chow KK; Lim M; Li G
    J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
    Zhang B; Shen R; Cheng S; Feng L
    Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.